Showing recent highlights
What's New
PubMed · December 1, 2026
Researchers found that mindfulness exercises delivered through virtual reality (VR) headsets — where people are immersed in a calming digital environment — may help reduce feelings of depression and anxiety. The effect appeared especially strong in older adults, which is noteworthy because this group can sometimes face barriers to accessing traditional in-person mental health support. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · November 15, 2026
Researchers found that people with psychotic depression — a severe form of depression that can include losing touch with reality — were nearly twice as likely to show meaningful improvement when treated with a combination of an antidepressant and an antipsychotic medication together, compared to taking just one type of medication alone. This could matter because psychotic depression is often harder to treat than typical depression, and finding more effective approaches is an important step forward. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 4, 2026
Researchers found that a brain stimulation technique called transcranial direct current stimulation (tDCS) — where a small, gentle electrical current is delivered to the scalp using a portable device — can modestly reduce depression symptoms when people use it at home with remote supervision, such as video check-ins with a clinician. This matters because many people with depression struggle to access in-person treatment, and a home-based option could make care more reachable. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · September 2, 2026
A study found that lumateperone (brand name Caplyta), a medication already used for certain mood and psychiatric conditions, helped improve sexual function in people with major depression who weren't getting enough relief from their antidepressant alone. Researchers found that when lumateperone was added to an existing antidepressant, patients — especially those who already had sexual dysfunction at the start of the study — saw meaningful improvements in sexual functioning over six weeks compared to those who received a placebo. This appears to be a new finding about a potential added benefit of the medication, not a safety warning or a guideline recommendation.
Ask your doctor: Ask the doctor whether adding lumateperone to the patient's current antidepressant might help with depression while also improving sexual function, since research shows it may help with both.
What's New
PubMed · September 2, 2026
A study found that pregnant women with depression or stress-related mental health conditions who used an app-based mindfulness program for 8 weeks — with no in-person therapist involved — showed reduced depression and anxiety symptoms compared to women who received their usual care alone. This could matter because it suggests a digital, self-guided tool might offer meaningful emotional relief during pregnancy, a time when many people prefer to avoid or limit medications. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with diabetes who took part in a short, four-week compassion meditation program — joining 30–40 minute recorded video sessions — felt less overwhelmed by their diabetes and more confident in managing it, compared to those who didn't meditate. Feeling less distressed and more in control can make it easier for people to stick to healthy habits like monitoring blood sugar and taking medications. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a structured self-management program — where people with chronic conditions like type 2 diabetes learn skills to manage their health day-to-day — led to lasting improvements in sleep, pain, fatigue, and mood, even six months after the program ended, across many different countries. For someone with type 2 diabetes, this matters because managing a long-term condition involves a lot more than just medication — things like energy levels, sleep, and emotional well-being all affect how well someone can stay on top of their health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a smartphone game designed to interrupt repetitive negative thinking — where the mind gets stuck replaying worries or painful thoughts over and over — helped reduce symptoms of depression and anxiety in adults with mild to moderate depression. The app seemed to work, at least in part, by breaking that cycle of stuck thinking, which researchers believe is a key driver of both depression and anxiety. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a free, self-guided online writing program called RECLAIM — designed to help transgender and gender-expansive adults work through the emotional weight of stigma and discrimination — showed early signs of reducing depression and anxiety symptoms in a group of 115 participants. The program encouraged people to write expressively about their experiences as a way to process difficult feelings and feel more connected to their community. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with depression or significant depressive symptoms who took vitamin D supplements tended to have lower symptom severity compared to those who didn't, based on a review of 13 studies. This is a meaningful signal because depression is very common and many people are also low in vitamin D, so an affordable, accessible supplement could potentially offer some added benefit alongside standard care. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that when people with depression or anxiety receive mental health support from trained non-specialists — like community health workers rather than therapists — certain specific parts of those treatments work better than others, and the best approach may vary depending on the individual person. The study looked at dozens of trials to figure out which building blocks of these programs actually drive improvement, with the goal of helping tailor care more personally. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a structured group therapy program focused on managing emotions helped people with a form of multiple sclerosis (MS) — a disease that affects the brain and nervous system — who were also living with excess weight. Participants who went through the 14-session program showed improvements in anxiety, depression, emotional eating, and even some physical health measures like body weight, compared to those who received standard medical care alone. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that among children and adolescents, getting enough quality sleep and being more physically active were consistently linked to fewer symptoms of depression, while disrupted sleep and poorer eating habits were linked to more symptoms. The connection between diet and depression was less clear-cut, with results varying across the studies reviewed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people with depression tend to have higher levels of certain inflammation markers in their blood — inflammation being the body's stress response that, when ongoing, can affect many systems including the brain. The review also found that the mix of bacteria living in people's mouths appears to be different in those with depression or anxiety compared to those without, though the exact significance of this is still unclear. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that psilocybin — a compound being studied as a fast-acting treatment for depression — appears to lower the levels of two specific chemical messengers in the brain called galanin and noradrenaline (these are substances your brain uses to send signals). This matters because scientists have been puzzled about exactly *how* psilocybin helps lift depression, and this finding offers a clue that calming down these particular brain chemicals may be part of the answer. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that people in prison who took part in physical activity programs — like structured exercise — showed meaningful improvements in anxiety and depression compared to those who didn't. This matters because prisons are high-stress environments where mental health struggles are very common, and exercise could be a low-cost way to help. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) — which uses magnetic pulses aimed at a specific area of the brain — may help ease depression in people who develop it after having a stroke. In the study, patients who received rTMS alongside their usual care showed noticeably greater improvements in both depression and anxiety symptoms compared to those who received usual care alone. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed (Open Access Guidelines) · September 1, 2026
A study found that lumateperone (brand name Caplyta), a newer medication approved in 2025 to help treat major depression when antidepressants alone aren't working well enough, showed strong results for reducing depression symptoms compared to a placebo — and performed as well as or better than several other similar medications already approved for this use, such as aripiprazole (Abilify) and quetiapine (Seroquel). Researchers also looked at side effects and found that lumateperone appeared to cause less weight gain and fewer movement-related side effects, like restlessness, than some of the other options studied. This is a new option for people whose depression hasn't fully responded to standard antidepressants, and the study is helping fill in the gaps in how it compares to existing choices — though as always, people should talk with their doctor about what might be right for their specific situation.
Ask your doctor: Ask the doctor whether lumateperone might be worth trying if the patient's depression isn't getting better with their current antidepressant alone, and how it compares to other add-on medications like aripiprazole or brexpiprazole.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
A study found that certain markers of inflammation — proteins in the blood that signal when the body's immune system is active — may be linked to how well people with depression respond to antidepressants. For example, people with lower levels of a protein called CRP before starting treatment seemed more likely to respond well to standard antidepressant medicines. This could matter because it hints that, one day, a simple blood test might help doctors choose the right treatment for someone whose depression hasn't improved — but this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that a therapy called behavioral activation — which helps people reconnect with enjoyable or meaningful activities to lift their mood — showed promising results for adolescents and young adults with depression. It worked especially well for those with milder symptoms and in university settings, where it showed a notably strong effect compared to no treatment at all. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that heart rate variability biofeedback — a technique where people use a small device to monitor and train their heart's rhythm patterns in order to calm the body's stress response — may help reduce stress, anxiety, and low mood when done remotely or with a portable device at home. All 13 studies reviewed showed improvement in at least one mental or physical stress measure, suggesting this kind of self-managed training could be a practical option for people managing anxiety. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that a technique called heart rate variability biofeedback — where people use guided breathing exercises, often with a device or app, to help regulate their nervous system — showed a meaningful benefit for reducing depression symptoms when delivered remotely, such as from home. The analysis looked at 18 studies involving more than 1,300 people and found that the approach also improved heart rate variability, which is a measure of how well the body's automatic functions, like heart rhythm, are adapting to stress. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that changing the mix of bacteria living in the gut — for example, by taking probiotics (live beneficial bacteria, often found in supplements or yogurt) or prebiotics (foods or supplements that feed those bacteria) — may help reduce symptoms of depression in some people who aren't taking antidepressants. Out of 66 studies reviewed, about half found meaningful improvements in depression symptoms compared to people who didn't receive these gut-focused treatments. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
A study found that people with depression or anxiety who experience high levels of anhedonia — a reduced ability to feel pleasure or enjoyment — may have a harder time responding to common treatments like therapy or medication, though the results across studies were mixed and not consistent. Researchers reviewed 28 studies and found that in about a third of them, feeling less pleasure before starting treatment was linked to poorer outcomes, while other studies found the opposite or no clear connection at all. Understanding what predicts whether a treatment will work could eventually help doctors tailor care more effectively for people who aren't improving. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that depression is surprisingly common among people with permanent vision loss — about 1 in 5 overall, but nearly 1 in 2 among those whose vision loss is linked to diabetes-related eye damage. Anxiety affects roughly 1 in 5 people with these conditions as well, suggesting that the emotional toll of losing vision is a serious and often overlooked part of the experience. For someone already living with depression, this research highlights how closely physical health challenges — like changes in eyesight — can be tied to mental wellbeing. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed (Open Access Guidelines) · September 1, 2026
Researchers found that people with depression who took SSRIs — a common type of antidepressant that includes medications like Prozac or Zoloft — did not appear to have a higher risk of stroke compared to people taking other types of antidepressants. The study looked at over 124,000 people and combined its findings with several other studies, all pointing in the same direction: no meaningful difference in stroke risk between the two groups. This could be reassuring for people with depression who have concerns about stroke risk, though they should always talk with their doctor about what's right for their situation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that an online therapy program called DadBooster — built around a well-known talk therapy approach called cognitive behavioral therapy, which helps people identify and change unhelpful thought patterns — may help fathers who are experiencing depression after the birth of a baby. Up to 1 in 10 new fathers go through this, yet they're much less likely than mothers to get support, so a program they can access from home could make a real difference in reaching people who might otherwise go without help. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that silexan — a lavender oil supplement — helped reduce several key symptoms of depression, including sadness, low energy, poor appetite, and trouble concentrating, about as well as the antidepressant sertraline (commonly known as Zoloft) in people with mild to moderate depression. The study tracked nearly 500 people over 8 weeks and found that those taking silexan did noticeably better than those taking a placebo (a dummy pill with no active ingredient). This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that certain natural supplements — including omega-3 fatty acids (healthy fats found in fish oil), vitamin D, and St. John's Wort (a herbal remedy) — showed promising signs of reducing depression symptoms compared to a placebo (a dummy treatment with no active ingredient) across a large analysis of 163 studies involving over 15,000 people. The results were encouraging, but the researchers also noted that some of the effects looked surprisingly large, which can be a sign that the studies had limitations worth scrutinizing. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that when ketamine — a medication sometimes used for hard-to-treat depression — is taken by mouth, most side effects appear to be mild and short-lived rather than serious or lasting. This matters for people with depression because oral ketamine could potentially be a more accessible option than the intravenous or nasal spray forms currently used in clinics, though researchers noted there is no standard dosing formula yet and long-term safety is still not fully understood. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.